Tocilizumab in pediatric refractory status epilepticus and acute epilepsy: Experience in two patients.
Clicks: 251
ID: 80637
2020
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Star Article
78.7
/100
251 views
201 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
There is growing evidence for inflammation as a cause and/or consequence of seizures in epilepsy as certain inflammatory biomarkers are elevated. Interleukin (IL)-6, with pro-inflammatory and epileptogenic effects, can perpetuate seizures. Clinical and experimental data support its involvement in acute refractory situations, with some cases responding to treatment with tocilizumab, a humanized monoclonal antibody against the IL-6 receptor. We describe 2 pediatric cases of refractory epilepsy with an abrupt debut responding to tocilizumab. Advances in the knowledge of inflammatory biomarkers involved in epilepsy and the targeted treatment could have important benefits, especially in cases that are refractory to usual treatments.| Reference Key |
cantarnextremera2020tocilizumabjournal
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | CantarĂn-Extremera, VerĂłnica;JimĂ©nez-Legido, MarĂa;Duat-RodrĂguez, Anna;GarcĂa-Fernández, Marta;Ortiz-Cabrera, Nelmar Valentina;Ruiz-FalcĂł-Rojas, MarĂa Luz;González-GutiĂ©rrez-Solana, Luis; |
| Journal | journal of neuroimmunology |
| Year | 2020 |
| DOI | S0165-5728(19)30492-8 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.